Turning Point Therapeutics Management
Management criteria checks 1/4
Turning Point Therapeutics' CEO is Athena Countouriotis, appointed in Sep 2018, has a tenure of 3.92 years. total yearly compensation is $16.94M, comprised of 3.8% salary and 96.2% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $8.39M. The average tenure of the management team and the board of directors is 2.3 years and 2 years respectively.
Key information
Athena Countouriotis
Chief executive officer
US$16.9m
Total compensation
| CEO salary percentage | 3.8% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report
Jul 21We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth
Mar 23
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth
Dec 06The Take On Turning Point Therapeutics
Dec 03Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts
Aug 15Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business
Aug 04Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer
Jun 17Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 08Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?
Feb 26Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study
Jan 29Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher
Jan 22
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn
Jan 13Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers
Dec 28Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?
Dec 15Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer
Dec 08Turning Point Therapeutics EPS beats by $0.12, beats on revenue
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2022 | n/a | n/a | -US$342m |
| Mar 31 2022 | n/a | n/a | -US$275m |
| Dec 31 2021 | US$17m | US$651k | -US$237m |
| Sep 30 2021 | n/a | n/a | -US$205m |
| Jun 30 2021 | n/a | n/a | -US$157m |
| Mar 31 2021 | n/a | n/a | -US$132m |
| Dec 31 2020 | US$15m | US$580k | -US$157m |
| Sep 30 2020 | n/a | n/a | -US$131m |
| Jun 30 2020 | n/a | n/a | -US$134m |
| Mar 31 2020 | n/a | n/a | -US$119m |
| Dec 31 2019 | US$3m | US$544k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$60m |
| Jun 30 2019 | n/a | n/a | -US$46m |
| Mar 31 2019 | n/a | n/a | -US$34m |
| Dec 31 2018 | US$9m | US$329k | -US$25m |
Compensation vs Market: Athena's total compensation ($USD16.94M) is above average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: Athena's compensation has increased whilst the company is unprofitable.
CEO
Athena Countouriotis (50 yo)
3.9yrs
Tenure
US$16,940,858
Compensation
Dr. Athena Maria Countouriotis, M.D. is Chief Executive Officer and Director at Turning Point Therapeutics, Inc. since September 2018. She has been Independent Director of Passage Bio, Inc since February 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.9yrs | US$16.94m | 0.22% $ 8.4m | |
| Executive VP & CFO | 1.1yrs | US$4.58m | 0.057% $ 2.2m | |
| Executive VP & Chief Medical Officer | 2.7yrs | US$5.61m | 0.082% $ 3.1m | |
| Senior VP & Chief Information Officer | no data | no data | no data | |
| Senior VP of Chemistry & Interim Chief Scientific Officer | no data | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | less than a year | no data | no data | |
| Senior VP & Chief Compliance Officer | no data | no data | no data | |
| Senior VP | less than a year | no data | no data | |
| Senior Vice President of Human Resources | 2.1yrs | no data | no data | |
| Senior Vice President of Pre-Clinical Development | no data | no data | no data | |
| Senior Vice President of Clinical Development | 3.6yrs | no data | no data | |
| Senior VP | 2.6yrs | no data | no data |
2.3yrs
Average Tenure
52yo
Average Age
Experienced Management: TPTX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.9yrs | US$16.94m | 0.22% $ 8.4m | |
| Chairman of Scientific Advisory Board | 2yrs | no data | no data | |
| Independent Director | 3.3yrs | US$424.79k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$415.29k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2yrs | no data | 0% $ 0 | |
| Independent Director | 2.6yrs | US$422.74k | 0% $ 0 | |
| Independent Non-Executive Director | 5.3yrs | US$414.41k | 0% $ 0 | |
| Independent Chairman of the Board | 1.3yrs | US$861.18k | 0.0040% $ 151.9k | |
| Independent Director | 1.4yrs | US$1.00m | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | 2yrs | no data | no data | |
| Member of the Scientific Advisory Board | 2yrs | no data | no data |
2.0yrs
Average Tenure
55.5yo
Average Age
Experienced Board: TPTX's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.